SOUTH
PLAINFIELD, N.J., Feb. 15,
2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:
PTCT) today announced that the company will host a webcast
conference call to report its fourth quarter and full year 2023
financial results and provide an update on the company's business
and outlook on Thursday, Feb. 29, at
4:30 p.m. EST.
To access the call by phone, please click here to register
and you will be provided with dial-in details. To avoid delays, we
recommend participants dial in to the conference call 15 minutes
prior to the start of the call. The webcast conference call can be
accessed on the Investor section of the PTC website at
https://ir.ptcbio.com/events-presentations. A replay of the call
will be available approximately two hours after completion
of the call and will be archived on the company's website for
30 days.
About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company focused on the
discovery, development, and commercialization of clinically
differentiated medicines that provide benefits to patients with
rare disorders. PTC's ability to innovate to identify
new therapies and to globally commercialize products is the
foundation that drives investment in a robust and diversified
pipeline of transformative medicines. PTC's mission is
to provide access to best-in-class treatments for patients who have
little to no treatment options. PTC's strategy is to
leverage its strong scientific and clinical expertise and global
commercial infrastructure to bring therapies to patients.
PTC believes this allows it to maximize value for all its
stakeholders. To learn more about PTC, please visit us
at www.ptcbio.com and follow
us on Facebook, Instagram, LinkedIn, and Twitter at
@PTCBio.
For More Information:
Investors:
Kylie O'Keefe
+1 (908) 300-0691
kokeefe@ptcbio.com
Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original
content:https://www.prnewswire.com/news-releases/ptc-therapeutics-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2023-financial-results-302062052.html
SOURCE PTC Therapeutics, Inc.